✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Rubicon Research Ltd.

RUBICON

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹10,296 Cr.
P/E
76.63

Rubicon Research Ltd.

Key Ratios

Edit Ratio's
Market cap
Market cap
10,296 Cr
PE
PE
76.63
Prom Holding
Prom Holding
59.99 %
ROE (%)
ROE (%)
24.84
ROCE (%)
ROCE (%)
34.85
Div Yield (%)
Div Yield (%)
-
Sales
Sales
708 Cr
OPM (%)
OPM (%)
22.03 %
Debt to Equity
Debt to Equity
0.76
View more
Edit Ratio's

About

Rubicon Research, established in 1999, is a pharmaceutical company focused on R&D-driven, diff… Read more
Low
571
52W Range
High
755
  • Rubicon Research
  • Sun Pharma Inds.
  • Aurobindo Pharma

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New
Edit rows

Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

3 No

Negative for this company

6 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Therapeutic Area Break-Up

Customer Wise Break-Up

Asset Break-Up - Geography Wise

Operational Metrics

    locked
    Select a Metric
    • Number of ANDA's Filed in USA (.)
      Source
    • Number of ANDA's Approved (.)
      Source
    • R&D as a % of Total Sales (%)
      Source

    Peer Comparison

    FAQs on Rubicon Research Ltd. Business

    Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. Further, the company has robust sales and distribution capabilities in the US.

    Rubicon Research major competitors are Sun Pharma Inds., Aurobindo Pharma, Zydus Lifesciences, Strides Pharma Scien, Dr. Reddy's Lab, Alembic Pharma, Lupin.
    Market Cap of Rubicon Research is ₹10,396 Crs.
    While the median market cap of its peers are ₹94,173 Crs.

    Rubicon Research seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    View FAQ's On Shareprice

    Company Filing

    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation Nov
    Conference Call Nov
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material